FDA Clears Updated AI Software for Generating Inline Mapping with Cardiac MRI
The AI-powered Tempus Pixel software update provides T1 and T2 inline maps to augment cardiac MRI assessment.
Facilitating rapid assessment and enhanced insights into subtle abnormalities on cardiac magnetic resonance imaging (MRI), the updated artificial intelligence (AI) software Tempus Pixel has garnered 510(k) clearance from the Food and Drug Administration (FDA).
Generating T1 and T2 inline maps from cardiac MRI, the updated Tempus Pixel software also provides numerical values for cardiac tissue characteristics, according to Tempus AI, the developer of the software.
Here one can see an example of T1 mapping with the newly FDA-cleared Tempus Pixel software update for cardiac MRI. (Image courtesy of Tempus AI.)
In addition to automated reporting capabilities, Tempus AI said the Tempus Pixel software update bolsters flow visualization and tissue characterization, which may aid in earlier detection of fibrosis, inflammation or edema.
“With inline maps generated by Tempus Pixel, cardiologists and radiologists gain a comprehensive view of heart tissue, enabling deeper insights into cardiac health and helping them deliver more precise, personalized care to their patients,” noted Chris Scotto DiVetta, the senior vice president of AI applications at Tempus AI.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Recent Videos
Related Content
